Form 4: Lyell Immunopharma VP Controller Reports RSU Grant, Tax Sale

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, reported the acquisition of 8,750 restricted stock units and the sale of 254 shares to cover tax obligations.

Summary

• Veronica Sanchez Bulis, VP, Corporate Controller of Lyell Immunopharma, Inc. (LYEL), reported transactions on February 10, 2026.
• Acquired 8,750 shares of Common Stock through a restricted stock unit (RSU) grant under the Issuer's 2021 Equity Incentive Plan.
• 12.5% of these RSUs will vest on August 9, 2026, with an additional 1/16th vesting quarterly thereafter, contingent on continued service.
• Disposed of 254 shares of Common Stock at a price of $23.12 per share.
• This disposition was an automatic sale to cover tax withholding obligations from the settlement of vested restricted stock units.
• Following these transactions, Veronica Sanchez Bulis beneficially owns 15,637 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and alignment with shareholder interests, offset by a routine tax-related share sale.

Positives

• The grant of 8,750 restricted stock units aligns management's interests with long-term shareholder value and incentivizes continued service.

Negatives

• The sale of 254 shares, although for tax purposes, slightly reduces direct beneficial ownership by the reporting person.

Future Outlook

The newly granted restricted stock units will begin vesting on August 9, 2026, with 12.5% vesting initially, followed by quarterly vesting of 1/16th of the total, subject to continued service.

Industry Context

StockSavvy.ai notes that RSU grants are a common compensation mechanism in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance. The tax-related sale is a standard practice for covering statutory withholding requirements upon RSU vesting.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are standard practice across many industries, particularly in high-growth sectors like biotech, to retain talent and incentivize long-term performance.
• Companies such as Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar equity compensation structures for their executives, often involving initial vesting periods followed by staggered quarterly or annual vesting.

Stakeholder Impact

• Shareholders: The RSU grant aligns management's interests with long-term shareholder value. The tax sale is a minor, routine event.
• Employees: The RSU grant is part of executive compensation, potentially signaling stability in executive retention.

Next Steps

• Continued vesting of restricted stock units according to the schedule, with the next vesting event on August 9, 2026.

Key Dates

Recommendation

This Form 4 reports routine insider transactions related to executive compensation (RSU grant and subsequent tax-related sale). It does not contain information that would fundamentally alter the investment thesis for Lyell Immunopharma, Inc. Therefore, a 'Hold' recommendation is appropriate as these events are expected and do not indicate a significant change in the company's prospects.

Keywords

Lyell Immunopharma, LYEL, Form 4, insider transaction, restricted stock units, RSU, stock grant, tax withholding, corporate controller